Skip to main content

Table 5 IPTp uptake against factors that affect access to health facility and health provider DOT adherence

From: Uptake of intermittent preventive treatment for malaria during pregnancy with Sulphadoxine-Pyrimethamine (IPTp-SP) among postpartum women in Zomba District, Malawi: a cross-sectional study

Characteristic N (Total = 426) % of women who took IPTp
≤2 doses 95%CI 3+ doses 95% CI
Took SP under DOTa each time
 Yes 376 252 (67.0) 62.1–71.6 124 (32.9) 28.4–37.9
 No 50 47 (94.0) 82.8–98.1 3 (6.0) 1.9–17.2
Distance to HF
 Small problem 348 233 (67.0) 61.8–71.7 115 (33.1) 28.3–38.2
 Big problem 78 66 (84.6) 74.7–91.1 12 (15.4) 8.9–25.3
Transport to HF
 Small problem 344 231 (67.2) 61.9–71.9 113 (32.9) 28.1–38.0
 Big problem 82 68 (82.9) 73.1–89.7 14 (17.1) 10.3–26.9
Worried no health provider at HF
 Small problem 280 183 (65.4) 59.6–70.7 97 (34.6) 29.3–40.4
 Big problem 146 116 (79.5) 72.1–85.3 30 (20.0) 14.7–27.9
Worried no drugs at HF
 Small problem 263 172 (65.4) 59.4–70.9 91 (34.6) 29.1–40.6
 Big problem 163 127 (77.9) 70.8–83.6 36 (22.1) 16.3–29.1
  1. aDirect Observation Therapy